"Our drug delivery system innovations seek to improve patient adherence" - Sunil Kumar Nataraj, DFE Pharma

DFE Pharma has more than 100 years of experience in developing and co-developing excipients for the pharmaceutical industry. In time, some dairy producers transformed into modern suppliers of lactose excipients.  

Our pharmaceutical grade lactose production started in 1960 and today the lactose products offered by DFE Pharma are suited for overcoming various manufacturing challenges. For example, the micro-crystals in our  SuperTab® 21AN product offers excellent compaction. The granular nature of our SuperTab® 24AN increases the compaction further with high drug loading possibilities.

DFE has also pushed the boundary with the launch of SuperTab® 40LL, a co-processed anhydrous lactose-lactitol product offering compaction levels similar to silicified microcrystalline cellulose (a widely-used excipient, with high compact-ability)

Since 1985, we have been providing advanced excipient solutions like inhalation grade lactose.

Inhalation grade lactose is a common and frequently used carrier in dry powder inhalation formulations. It is popularly used in pulmonary drug delivery, since it minimizes dose variability. 

Being a global player, we operate in over 100 countries and have our own sales offices in Germany, the United States, Singapore, Japan and India. The geographical spread of our production plants enables us to guarantee security of supply, as we offer dual sourcing to our customers thereby lowering our customers’ supply chain risks.

Our heritage, along with our geographical footprint, allows us to support accelerated drug product launches so that our customers get the necessary market advantage.